Posaconazole SP

RSS

posaconazole

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Posaconazole SP has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.

This EPAR was last updated on 04/08/2009

Authorisation details

Product details
Name
Posaconazole SP
Agency product number
EMEA/H/C/000611
Active substance
posaconazole
International non-proprietary name (INN) or common name
posaconazole
Therapeutic area (MeSH)
  • Candidiasis
  • Mycoses
  • Coccidioidomycosis
  • Aspergillosis
Anatomical therapeutic chemical (ATC) code
J02AC04
Publication details
Marketing-authorisation holder
Schering-Plough Europe
Revision
5
Date of issue of marketing authorisation valid throughout the European Union
25/10/2005
Contact address
SP Europe
Rue de Stalle, 73
B-1180 Bruxelles
Belgium

Product information

04/12/2008 Posaconazole SP - EMEA/H/C/000611 - II/0011

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antimycotics for systemic use

Therapeutic indication

Posaconazole SP is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):
- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;
- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;
- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;
- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;
- Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.
Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.
Posaconazole SP is also indicated for prophylaxis of invasive fungal infections in the following patients:
- Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are
at high risk of developing invasive fungal infections;
- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.

Assessment history

How useful was this page?

Add your rating